FYI..: prnewswire.com/news-release... - Ataxia UK
FYI..
Written by
nycgeordie
To view profiles and participate in discussions please or .
1 Reply
•
🙂 I saw this yesterday..I hope it’s the start of good things to come
Copied from the link..
NEW YORK, Oct. 25, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced dosing of the first patient in a registrational phase II/III study of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of spinocerebellar ataxia focusing on participants with type3 (SCA3, also known as Machado-Joseph disease) and also announced that it will participate in the International Congress for Ataxia Research (ICAR) in Dallas, Texas November 1st – 4th, 2022.
